Clinical Trials Logo

Clinical Trial Summary

This study is a longer-term follow-up study for patients who participated in one of the clinical trials: AAV - CNGB3 retinal gene therapy for patients with achromatopsia, or AAV - CNGA3 retinal gene therapy for patients with achromatopsia.


Clinical Trial Description

The follow up study is designed to collect data on longer-term safety and efficacy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03278873
Study type Interventional
Source MeiraGTx UK II Ltd
Contact
Status Active, not recruiting
Phase Phase 1/Phase 2
Start date June 29, 2017
Completion date January 15, 2026

See also
  Status Clinical Trial Phase
Completed NCT04124185 - Natural History Study for Achromatopsia
Recruiting NCT02610582 - Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia Phase 1/Phase 2
Not yet recruiting NCT04041232 - PBA Use for Treatment of ATF6-/- Patients Early Phase 1
Recruiting NCT02435940 - Inherited Retinal Degenerative Disease Registry
Completed NCT01846052 - Clinical and Genetic Characterization of Individuals With Achromatopsia N/A
Active, not recruiting NCT01648452 - CNTF Implants for CNGB3 Achromatopsia Phase 1/Phase 2
Completed NCT03001310 - Gene Therapy for Achromatopsia (CNGB3) Phase 1/Phase 2
Active, not recruiting NCT02935517 - Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial) Phase 1/Phase 2
Completed NCT03758404 - Gene Therapy for Achromatopsia (CNGA3) Phase 1/Phase 2
Active, not recruiting NCT02599922 - Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial) Phase 1/Phase 2